214 related articles for article (PubMed ID: 11249521)
1. Thalidomide: a remarkable comeback.
Jacobson JM
Expert Opin Pharmacother; 2000 May; 1(4):849-63. PubMed ID: 11249521
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide: current and potential clinical applications.
Calabrese L; Fleischer AB
Am J Med; 2000 Apr; 108(6):487-95. PubMed ID: 10781782
[TBL] [Abstract][Full Text] [Related]
3. [Thalidomide: new uses for an old drug].
Wu KL; Sonneveld P
Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1438-41. PubMed ID: 12190008
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicity.
Breitkreutz I; Anderson KC
Expert Opin Drug Metab Toxicol; 2008 Jul; 4(7):973-85. PubMed ID: 18624684
[TBL] [Abstract][Full Text] [Related]
5. Thalidomide: rationale for renewed use in immunological disorders.
Schuler U; Ehninger G
Drug Saf; 1995 Jun; 12(6):364-9. PubMed ID: 8527011
[TBL] [Abstract][Full Text] [Related]
6. Thalidomide: a review of approved and investigational uses.
Matthews SJ; McCoy C
Clin Ther; 2003 Feb; 25(2):342-95. PubMed ID: 12749503
[TBL] [Abstract][Full Text] [Related]
7. Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing.
Clark TE; Edom N; Larson J; Lindsey LJ
Drug Saf; 2001; 24(2):87-117. PubMed ID: 11235821
[TBL] [Abstract][Full Text] [Related]
8. Thalidomid: current role in the treatment of non-plasma cell malignancies.
Kumar S; Witzig TE; Rajkumar SV
J Clin Oncol; 2004 Jun; 22(12):2477-88. PubMed ID: 15197211
[TBL] [Abstract][Full Text] [Related]
9. Adverse effects of thalidomide administration in patients with neoplastic diseases.
Dimopoulos MA; Eleutherakis-Papaiakovou V
Am J Med; 2004 Oct; 117(7):508-15. PubMed ID: 15464708
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide: an old drug with new clinical applications.
Laffitte E; Revuz J
Expert Opin Drug Saf; 2004 Jan; 3(1):47-56. PubMed ID: 14680461
[TBL] [Abstract][Full Text] [Related]
11. Dermatologic and nondermatologic uses of thalidomide.
Nasca MR; Micali G; Cheigh NH; West LE; West DP
Ann Pharmacother; 2003 Sep; 37(9):1307-20. PubMed ID: 12921515
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacology of thalidomide.
Eriksson T; Björkman S; Höglund P
Eur J Clin Pharmacol; 2001 Aug; 57(5):365-76. PubMed ID: 11599654
[TBL] [Abstract][Full Text] [Related]
13. Thalidomide: an antineoplastic agent.
Amato RJ
Curr Oncol Rep; 2002 Jan; 4(1):56-62. PubMed ID: 11734114
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide: emerging role in cancer medicine.
Richardson P; Hideshima T; Anderson K
Annu Rev Med; 2002; 53():629-57. PubMed ID: 11818493
[TBL] [Abstract][Full Text] [Related]
15. [Thalidomide: new perspectives for its use as antiinflammatory, immunossupressive and antiangiogenic drug].
Borges Lde G; Frõehlich PE
Rev Assoc Med Bras (1992); 2003; 49(1):96-102. PubMed ID: 12724820
[TBL] [Abstract][Full Text] [Related]
16. Thalidomide and its impact in dermatology.
Stirling DI
Semin Cutan Med Surg; 1998 Dec; 17(4):231-42. PubMed ID: 9859910
[TBL] [Abstract][Full Text] [Related]
17. [Thalidomide in treatment of connective diseases and vasculities].
Maruotti N; Cantatore FP; Ribatti D
Reumatismo; 2006; 58(3):187-90. PubMed ID: 17013434
[TBL] [Abstract][Full Text] [Related]
18. Potential novel uses of thalidomide: focus on palliative care.
Peuckmann V; Fisch M; Bruera E
Drugs; 2000 Aug; 60(2):273-92. PubMed ID: 10983733
[TBL] [Abstract][Full Text] [Related]
19. [The revival of thalidomide: an old drug with new indications].
Laffitte E
Rev Prat; 2006 Nov; 56(18):1977-83. PubMed ID: 17274497
[TBL] [Abstract][Full Text] [Related]
20. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses.
Tseng S; Pak G; Washenik K; Pomeranz MK; Shupack JL
J Am Acad Dermatol; 1996 Dec; 35(6):969-79. PubMed ID: 8959957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
